GE HealthCare Technologies Inc. (GEHC)
Stock Of The Day: Where Will The GE HealthCare Rally End?
GE HealthCare Technologies Inc. GEHC shares are trading higher Wednesday. The stock was upgraded from Hold to Buy, while the price target was raised from $95 to $103 by Jefferies.
GEHC vs. PODD: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2025 Could Be GE HealthCare's Year With Emphasis On Efficiency And AI Broadens
GE HealthCare shares have surged nearly 27% since October 2023, driven by AI-driven strategies and innovation in healthcare diagnostics, despite some volatility in revenue growth. The bullish outlook for 2025 is supported by GEHC's AI advancements, expected sales and profitability improvements, and a significant backlog of $19.6 billion. AI-driven healthcare solutions are projected to enhance diagnostic accuracy, reduce treatment costs, and drive market growth, with GEHC positioned as a leader with numerous FDA-approved devices.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GE HealthCare: Growth Acceleration In 2025 Can Drive Stock Higher
GE HealthCare Technologies is rated a buy due to strong growth prospects, a healthy backlog, and favorable valuation compared to peers. The company's revenue growth is supported by new product innovations, including the FDA-approved Flyrcado, and potential recovery in Chinese demand. Margins are expected to improve through cost optimization, volume leverage, and strategic pricing, with a medium-term EBIT margin target of high teens to 20%.
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL
GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL
GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging
GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care
The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.
GEHC Stock May Gain Following the Launch of Pristina Via System
GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.
GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio
GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.
